Cost Effectiveness of Sucroferric Oxyhydroxide Compared with Sevelamer Carbonate in the Treatment of Hyperphosphataemia in Patients Receiving Dialysis, from the Perspective of the National Health Service in Scotland

BACKGROUND: Hyperphosphataemia is common and harmful in patients receiving dialysis. Treatment options include noncalcium-based phosphate binders such as sevelamer carbonate (SC) and sucroferric oxyhydroxide (PA21). OBJECTIVE: The aim of this study was to determine the health economic impact of PA21...

Descripción completa

Detalles Bibliográficos
Autores principales: Gutzwiller, Florian S., Pfeil, Alena M., Ademi, Zanfina, Blank, Patricia R., Braunhofer, Peter G., Szucs, Thomas D., Schwenkglenks, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2015
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4661221/
https://www.ncbi.nlm.nih.gov/pubmed/26334991
http://dx.doi.org/10.1007/s40273-015-0320-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4661221/
https://www.ncbi.nlm.nih.gov/pubmed/26334991
http://dx.doi.org/10.1007/s40273-015-0320-9

Ejemplares similares